A loss of mature microglial markers without immune activation in schizophrenia

Citation for published version:
Snijders, GJLJ, Zuiden, W, Sneeboer, MAM, Berdenis Van Berlekom, A, Geest, AT, Schnieder, T, MacIntyre, DJM, Hol, EM, Kahn, RS & Witte, LD 2021, 'A loss of mature microglial markers without immune activation in schizophrenia', Glia. https://doi.org/10.1002/glia.23962

Digital Object Identifier (DOI):
10.1002/glia.23962

Link:
Link to publication record in Edinburgh Research Explorer

Document Version:
Publisher's PDF, also known as Version of record

Published In:
Glia

General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer content complies with UK legislation. If you believe that the public display of this file breaches copyright please contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and investigate your claim.
A loss of mature microglial markers without immune activation in schizophrenia

Gijsje J. L. J. Snijders1,2 | Welmoed van Zuiden2 | Marjolein A. M. Sneeboer3 | Amber Berdenis van Berlekom1,3 | Astrid T. van der Geest3 | Tatiana Schnieder4 | Donald J. M. MacIntyre5 | Elly M. Hoij3,6 | René S. Kahn2,7 | Lot D. de Witte1,2,7

1Department of Psychiatry, University Medical Center Utrecht Brain Center, Utrecht University, Brain Center Rudolf Magnus, University Medical Center Utrecht, Utrecht, The Netherlands
2Department of Psychiatry, Icahn School of Medicine, New York, New York
3Department of Translational Neuroscience (BCRM-UMCU-UU), Utrecht, The Netherlands
4Department of Psychiatry, Columbia University, New York, New York
5Division of Psychiatry, Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, UK
6Neuroimmunology, Netherlands Institute for Neuroscience, An Institute of the Royal Academy of Arts and Sciences, Amsterdam, The Netherlands
7Mental Illness Research, Education and Clinical Center (MIRECC), James J Peters VA Medical Center, Bronx, New York

Correspondence
Lot D. de Witte, Department of Psychiatry, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, Box 1230, New York, NY.
Email: lotje.dewitte@mssm.edu

Funding information
Prins Bernard Culture Fund; Jo Kolk Study fund; Catharina van Tussenbroek Fund; Medical Research Council, Grant/Award Number: MR/L016400/1; Netherlands Organization for Scientific Research (NWO)

Abstract
Microglia, the immune cells of the brain, are important for neurodevelopment and have been hypothesized to play a role in the pathogenesis of schizophrenia (SCZ). Although previous postmortem studies pointed toward presence of microglial activation, this view has been challenged by more recent hypothesis-driven and hypothesis-free analyses. The aim of the present study is to further understand the observed microglial changes in SCZ. We first performed a detailed meta-analysis on studies that analyzed microglial cell density, microglial morphology, and expression of microglial-specific markers. We then further explored findings from the temporal cortex by performing immunostainings and qPCRs on an additional dataset. A random effect meta-analysis showed that the density of microglial cells was unaltered in SCZ (ES: 0.144 95% CI: 0.102 to 0.390, p = .250), and clear changes in microglial morphology were also absent. The expression of several microglial specific genes, such as CX3CR1, CSF1R, IRF8, OLR1, and TMEM119 was decreased in SCZ (ES: −0.417 95% CI: −0.417 to −0.546, p < .0001), consistent with genome-wide transcriptome meta-analysis results. These results indicate a change in microglial phenotype rather than density, which was validated with the use of TMEM119/Iba1 immunostainings on temporal cortex of a separate cohort. Changes in microglial gene expression were overlapping between SCZ and other psychiatric disorders, but largely opposite from changes reported in Alzheimer’s disease. This distinct microglial phenotype provides a crucial molecular hallmark for future research into the role of microglia in SCZ and other psychiatric disorders.

KEYWORDS
gene expression, immunology, microglia, postmortem, schizophrenia

1 | INTRODUCTION

Genetic and epidemiological studies have suggested a causal role for the immune system in schizophrenia (SCZ) pathogenesis (Benros et al., 2014; Pouget et al., 2019; Ripke et al., 2014; Sekar et al., 2016; van Mierlo, Schot, Boks, & de Witte, 2019). This is supported by changes in immune-related markers reported in blood, cerebrospinal fluid, and brain tissue of SCZ patients (Gandal et al., 2018;
Upthegrove, Manzanares-Teson, & Barnes, 2014; Wang & Miller, 2018). It has, therefore been hypothesized that microglia, the immune cells of the brain, play an important role in SCZ (Howes & McCutcheon, 2017). Microglia are part of the innate immune system and regulate inflammatory responses in the central nervous system (CNS) (Tambuyzer, Ponsaerts, & Nouwen, 2009). Microglia also control synaptic pruning, a process thought to be dysregulated in SCZ (Berdenis van Berlekom et al., 2019). Synaptic pruning is required for normal brain development and is mediated through the complement cascade (Stephan, Barres, & Stevens, 2012). Copy number variants in complement factor 4A (C4A) are associated with SCZ (Sekar et al., 2016), and increased synaptic pruning was observed in patient-derived microglial cell cultures (Sellgren et al., 2019).

Many brain disorders coincide with microglial activation, a state characterized by an increased cell density, and a morphological shift from ramified toward amoeboid, and upregulated expression of several inflammatory molecules (Kettenmann, Hanisch, Noda, & Verkhovsky, 2011). A previous review and independent meta-analysis (Trépanier, Hopperton, Mizrahi, Mechawar, & Bazinet, 2016; Van Kesteren et al., 2017) suggested an activated microglia phenotype in postmortem brain tissue of patients with SCZ. However, these reviews also noted substantial heterogeneity between studies, and a generally limited number of subjects, ranging from \( N = 5 \)–\( 35 \). This heterogeneity is probably caused by a large variety of pre- and postmortem confounders, methodological differences, and analysis of divergent brain regions (Powchik et al., 1998). In addition, samples that partially overlapped between the studies were included in the meta-analysis. In contrast, three recent genome-wide transcriptomic studies on SCZ postmortem brain tissue, with sample sizes ranging from \( N = 159 \)–\( 559 \) patients (Bergon et al., 2015; Gandal et al., 2018; Gandal, Zhang, et al., 2018), did not find increased expression of most of these microglial markers. Instead, the expression of several well-known microglial genes, such as CX3CR1, TMEM119, TREM2, CSF1R, CD86, and OLR1, were downregulated in one or more of these studies.

The goal of the present study was to better understand these reported microglial changes in schizophrenia. Our aim was to provide an up-to-date overview of hypothesis-driven studies that analyzed microglial density, morphology, and expression of microglial-specific genes. We performed a structural review followed by a qualitative and quantitative assessment of the selected studies. We included an additional dataset using postmortem samples from the Netherlands (NBB) and Edinburgh Brain Banks (EBB) to explore previous significant microglial findings in the temporal cortex (Van Kesteren et al., 2017). In addition, we further elucidate changes in mRNA expression identified by the aforementioned hypothesis-free transcriptomic studies on bulk brain tissue (Gandal, Zhang, et al., 2018). By applying a recently published core microglial signature (Patir, Shih, McColl, & Freeman, 2019) on this dataset we identified up- and downregulated genes that are likely to reflect changes in microglia. We analyzed how these microglia-related changes overlap with gene expression changes in other disorders, such as autism spectrum disorder (ASD), bipolar disorder (BPD), and Alzheimer’s disease (AD). Altogether, this study provides an overview of microglial changes in postmortem brain tissue of patients with SCZ.

## MATERIAL AND METHODS

### 2.1 Meta-analysis

The quantitative review was performed according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) (Liberati et al., 2009). We performed two separate systematic searches for articles analyzing microglial density and morphology changes or changes in microglial-specific gene expression. We used PubMed and EMBASE, and checked references of included studies and previous reviews (Suzuki et al., 2019; Trépanier et al., 2016; Van Kesteren et al., 2017). We used the following search terms: (a) (postmortem OR postmortem OR autopsy) AND (schizophrenia* OR psychotic OR psychosis) AND (microglio* OR macrophage*); (b) (postmortem OR postmortem OR autopsy) AND (AIF1 OR IBA1 OR Iba-1 OR CD68 OR NOX2 OR CYBB OR HLA-DR* OR HLA-DR OR P2RY12 OR P2Y12 OR TMEM119 OR CX3CR1 OR ITGB2 OR ITGAX OR CD11c OR GPR34 OR CSF1R OR IRF8 OR TGFBI OR TREM2 OR DAP12 OR TYROBP OR OLR1) AND (schizophrenia* OR psychotic OR psychosis). The microglia markers \( n = 17 \) were selected because they were used as microglia markers in studies that came out of our first search and recent reviews (Trépanier et al., 2016; Van Kesteren et al., 2017), or that have been more recently described as microglia-specific markers (Bennett et al., 2016; Butovsky et al., 2014). Furthermore, these markers are specifically expressed in microglia compared to other cells in the CNS and are all part of a defined microglial signature recently described by (Patir et al., 2019). We excluded transcriptomic studies (micro-array and RNA sequencing) from the meta-analysis, since we assumed a high chance of selection/reporting bias, as only significant results were reported in most of these studies. However, to validate our meta-analysis findings, we extracted results from the largest transcriptomic study in SCZ to date, which includes data on all detected genes (Gandal, Zhang, et al., 2018). The search cut-off date was February 28, 2020. Screening and selection of studies were performed independently by three authors (GS, WZ, and LW). Disagreements were resolved through discussion.

### 2.1.2 Inclusion criteria

Pre-specified inclusion criteria were: (a) human postmortem studies; comparing (b) patients with a diagnosis of SCZ with (c) healthy controls; (d) measuring microglial density or gene expression of microglial markers; (e) original research, published in a peer-reviewed journal; and (f) written in English.

### 2.1.3 Qualitative assessment

Several criteria were assessed to evaluate the quality of the included studies. Study design was rated for the following aspects: blinding researchers to diagnostic or clinical information, neuropathological...
defined as those with standardized residual test (which was considered significant if the one-sided $p$-value was less than $0.05$ two tailed). The potential for publication bias was assessed by visual examination of Funnel plots and by the Egger’s test (which was considered significant if the one-sided $p$-value was less than $0.10$) (Egger, Smith, Schneider, & Minder, 1997). Random-effects meta-regression analyses were performed to analyze the role of potential confounding factors (age, sex, PMI, pH). An exploratory subgroup analysis was performed on biological variables (brain regions, technical variation (methods, outcome measures) to assess sources of heterogeneity. We grouped outcomes for analyzing different brain regions in four subgroups: frontal cortex (including the dorsal, ventral, and dorsolateral prefrontal cortex, orbitofrontal cortex, midfrontal cortex, entorhinal cortex), temporal cortex, occipital cortex and limbic system (including the mid/anterior) cingulate cortex, hippocampus, amygdala, thalamus, dorsal raphe nucleus, basal ganglia). A common among-study variance was assumed across different subgroups, and within-group estimates of tau-squared were pooled. Between-group differences were tested using the $Q$-test based analysis of variance to determine whether the variance within subgroups was significantly smaller than the variance of all the combined data ($Q_{between} = Q_{total} - (Q_{SubgroupA} + Q_{SubgroupB})$. Cell density and gene expression studies were analyzed separately. For the microglial cell density studies, each study included only one marker (or a double staining) as outcome measurement, but various studies included multiple brain regions. Microglial cell density and gene expression measurements in different brain regions within the same cohort/study are not independent of each other. To prevent overrepresentation of the results from studies analyzing multiple brain regions in our analysis across all brain regions, we therefore used a conservative approach and nested data by computing combined scores from all measurements across different brain regions within one study. Forest plots of unmasked data are depicted in the Figures of Supporting Information.

### 2.14 Data extraction

When data records in the original article were not given or insufficient to generate effect sizes, corresponding authors were asked to provide raw data. In the case of follow-up data, included outcomes of the largest sample size were included. If data were not reported numerically in the manuscript, data was extracted using https://automeris.io/WebPlotDigitizer/. The following variables were extracted for potential moderator analyses: sample size, methods, brain bank, brain region and area (cortical or subcortical), age, sex, postmortem interval (PMI), and pH (Tables S6, S7, S8, S12 and S13).

### 2.15 Statistical approach meta-analysis

Meta-analyses were carried out using the Comprehensive Meta-Analysis (CMA) software developed by Biostat (Borenstein, Hedges, Higgins, & Rothstein, 2009). Change in microglial number or microglial gene expression per brain (sub)region was used to quantify effect size (ES) between SCZ and controls. We used sample size, mean, and standard deviation (SD) to generate ES. Hedge’s $g$ and the upper/lower limit of the 95% CI were used to express ES. Given the heterogeneity among studies, we used a random effects model for all comparisons (Higgins, Thompson, & Spiegelhalter, 2009). The Cochran’s $Q$-statistic test, displaying a chi-square distribution with $k – 1$ degrees of freedom, was performed to evaluate the existence of heterogeneity. High $Q$-values indicate that the variability among studies is higher than would be expected due to randomness, and further examination of subgroups is warranted. $I$-squared ($I^2$) was calculated to estimate the amount of heterogeneity. $I^2$ reflects which proportion of the observed variance reflects differences in true effect size rather than sampling error (range 0–100%). High $Q$-outlier studies were defined as those with standardized residual $z$-scores of effect sizes exceeding $\pm 1.96$ ($p \leq 0.05$ two tailed). The potential for publication bias was assessed by visual examination of Funnel plots and by the Egger’s test (which was considered significant if the one-sided $p$-value was $\leq 0.10$) (Egger, Smith, Schneider, & Minder, 1997). Random-effects meta-regression analyses were performed to analyze the role of potential confounding factors (age, sex, PMI, pH). An exploratory subgroup analysis was performed on biological variables (brain regions, technical variation (methods, outcome measures) to assess sources of heterogeneity. We grouped outcomes for analyzing different brain regions in four subgroups: frontal cortex (including the dorsal, ventral, and dorsolateral prefrontal cortex, orbitofrontal cortex, midfrontal cortex, entorhinal cortex), temporal cortex, occipital cortex and limbic system (including the mid/anterior) cingulate cortex, hippocampus, amygdala, thalamus, dorsal raphe nucleus, basal ganglia). A common among-study variance was assumed across different subgroups, and within-group estimates of tau-squared were pooled. Between-group differences were tested using the $Q$-test based analysis of variance to determine whether the variance within subgroups was significantly smaller than the variance of all the combined data ($Q_{between} = Q_{total} - (Q_{SubgroupA} + Q_{SubgroupB})$. Cell density and gene expression studies were analyzed separately. For the microglial cell density studies, each study included only one marker (or a double staining) as outcome measurement, but various studies included multiple brain regions. Microglial cell density and gene expression measurements in different brain regions within the same cohort/study are not independent of each other. To prevent overrepresentation of the results from studies analyzing multiple brain regions in our analysis across all brain regions, we therefore used a conservative approach and nested data by computing combined scores from all measurements across different brain regions within one study. Forest plots of unmasked data are depicted in the Figures of Supporting Information.

### 2.2 SCZ cohort

#### 2.2.1 Human brain tissue

Paraffin-embedded and frozen postmortem samples of the superior temporal gyrus were provided by the Netherlands (Rademaker, de Lange, & Palmen, 2018) and Edinburgh Brain Banks (Millar et al., 2007) (NBB and EBB). The permission to collect human brain material was obtained from the Ethical Committee of the VU University Medical Center, Amsterdam, The Netherlands, and the East of Scotland Research Ethics Service REC1. Permission for brain autopsy and the use of brain tissue and accompanying clinical information for research purposes was obtained per donor ante-mortem. Control donors were defined as donors without a clinical diagnosis of a major depressive disorder, bipolar disorder, or psychotic disorder according to the DSM-IV, DSM-III-R, or DSM-III. If the DSM classification was not available, the DSM characterization was based on retrospective medical chart review by two independent psychiatrists. Cases clinically diagnosed with Alzheimer’s or Parkinson’s disease, Amyotrophic Lateral Sclerosis, Multi System Atrophy, or brain diseases caused by an infection (meningitis and encephalitis) were excluded. There was no significant difference between controls and patients in age, sex, postmortem interval (PMI), or pH (Table S1). Detailed clinicopathological information per donor is provided in Table S2.

#### 2.2.2 Iba1 immunohistochemistry

Microglial density and morphology were characterized by ionized calcium-binding adapter molecule 1 (Iba1) immunohistochemistry as described before (Sneeboer et al., 2019). Paraffin-embedded tissue of
the superior temporal gyrus was sectioned at 7 μm for SCZ patients (N = 12) and controls (N = 16). The sections were deparaffinized using a standard xylene and alcohol series, followed by blocking of endogenous peroxidase with PBS, 1% H2O2 (Merck, Germany). For antigen retrieval, sections were heated in 0.01 mM citrate buffer (Merck, Darmstadt, Germany), 0.05% Tween-20 (Merck, Darmstadt, Germany), pH = 6.0 for 15 min. Subsequently, nonspecific binding was blocked in PBS with 1% normal horse serum, sections were incubated with a rabbit polyclonal anti-Iba1 antibody (Wako Pure Chemical Industries, Ltd., 1:1000) at 4°C. Next day, secondary goat-anti-rabbit biotin (Jackson ImmunoResearch Laboratories, Inc., 1:400) was added, followed by avidin-biotin-peroxidase (DAKO). Finally, tissue sections were dehydrated through an alcohol and xylene series and embedded in Entellan (Merck, Darmstadt, Germany). The sections were stained with a 3,3′′-diaminobenzidine (DAB) substrate (DAKO). Tissue sections were counterstained with a Zeiss Imager M2 light microscope. 

2.2.3 | Iba1/TMEM119 immunofluorescence

Immunofluorescence double staining with Iba1 and Transmembrane Protein 119 (TMEM119) antibodies was performed by sectioning paraffin-embedded tissue of the superior temporal gyrus at 7 μm for SCZ patients (N = 18) and controls (N = 19). After deparaffinization, blocking of endogenous peroxidase, antigen retrieval, and blocking of nonspecific binding with normal horse serum, sections were incubated with a polyclonal goat anti-Iba1 antibody Ab5076 (Abcam) and a polyclonal rabbit anti-TMEM119 antibody HPA051870 (Atlas Antibodies). This was followed by staining with donkey anti-rabbit Alexa Fluor 488 and donkey anti-goat Cy3 antibodies (Jackson ImmunoResearch Laboratories), as well as Hoechst (Thermo Scientific). Images (615 × 450 µm) of six randomly selected areas throughout the grey matter of the cortex were collected with a Zeiss Axio Scope A1 fluorescence microscope. Most cells were positive for both Iba1 and TMEM119. While we only rarely observed cells that were TMEM119− and Iba1−, we found a variable degree of Iba1+/TMEM119− across donors. To analyze case-control differences, we calculated the percentage of TMEM119+/Iba1− by dividing the number of TMEM119+/Iba1− cells by the total number of Iba1+ cells, both manually counted.

2.2.4 | Gene expression analysis

Five 50 μm sections of grey matter of the superior temporal gyrus were dissected manually from cryosections for SCZ patients (N = 9) and controls (N = 14). RNA was isolated using Trizol reagent (Thermo Fisher Scientific, MA), followed by addition of 100 μl chloroform and centrifugation at 12,000 rcf at 7°C for 15 min. Subsequently, RNA was precipitated from 100-200 μl of the aqueous top phase by mixing with an equal volume of isopropanol, using 1 μl glycogen as a carrier, and stored overnight at −20°C. The next day, samples were centrifuged at maximum speed at 4°C for 60 min. The pellet was washed twice with 75% ETOH, air-dried, and dissolved in 8 μl Milli-Q water. Concentrations of extracted RNAs were measured using a nanodrop (ND-1000; NanoDrop Technologies, Rockland, DE). RNA was reverse transcribed using a Quantitect Reverse Transcription kit (QIAGEN, Hilden, Germany) according to the manufacturer’s protocol. RNA supplemented with Milli-Q water to a volume of 6 μl was mixed with 1 μl gDNA Wipe-Out buffer and incubated at 42°C for 2 min. After addition of the master mix containing 2 μl Reverse-Transcriptase buffer, 0.5 μl Reverse-Transcriptase enzyme, and 0.5 μl RT random hexamers primer mix, samples were incubated at 42°C for 30 min, followed by 95°C for 3 min. Samples were subsequently stored at −20°C until further use. Quantitative real-time polymerase chain reaction (qPCR) was performed on a QuantStudio™ 6 Flex Real-Time PCR System (Life Technologies Corporation, NY). Per reaction, 3.5 ng input of cDNA was mixed with Milli-Q water, 5 μl SYBRgreen PCR Master Mix (Roche; Life Technologies Corporation, NY), and 1 μl primer mix (2 pmol/μl; see Table S3) until a final volume of 11 μl. All primers were intron-spanning and designed with the online tool of NCBI. The following cycle conditions were used: 50°C for 2 min, 95°C for 10 min, 40 cycles at 95°C of 15 s, and at 60°C for 60 s. Gene expression was normalized to reference genes (Glyceraldehyde 3-phosphate dehydrogenase (GAPDH), β-actin (ACTB), and Succinate Dehydrogenase Complex Flavoprotein Subunit A (SDHA)) according to the ΔΔCT method. These genes were selected from a larger set of housekeeping genes based on the Vandesompele method (Vandesompele et al., 2002). Gene expression values were compared with other gene expression studies by dividing the mean ΔCT scores.
of SCZ patients by the mean of the controls and applying a log2 transformation. The relative gene expression was expressed as a log2 fold change (log2FC) value.

2.2.5 | Statistics

Statistical analysis was performed with SPSS IBM 25. Assumption of normality was tested by visual checks using histograms and by the Shapiro Wilk test. Mann–Whitney U tests were applied to test the differences between patients and controls. Spearman rank correlation tests were used to determine the relation between age, PMI, pH, sex, and microglial density (Iba1^+ -cells/mm^2 and total Iba1^+ -area covered) and the microglial gene expression analysis. Subsequently, an ANCOVA analysis was performed to study the interaction effects of these covariates on microglial density and microglial gene expression. In the case of non-normally distributed data, log transformation was used. Results were adjusted for multiple testing by dividing the probability level of p < .05 by the number of performed tests.

2.3 | Cross-disorder comparison of microglial gene expression changes

We used a recently identified core signature of N = 249 genes that are specifically expressed by microglia compared to other CNS cell types (Patir et al., 2019). We extracted differential gene expression data of these genes (log2 fold changes) from the largest bulk brain tissue transcriptome studies on SCZ (Gandal, Zhang, et al., 2018), BD (Gandal, Zhang, et al., 2018), ASD (Gandal, Zhang, et al., 2018), and AD (Friedman et al., 2018). Correlations between log2 fold changes in different conditions and the significance of these correlations were calculated with the R function rcorr in R package Hmisc (Harrell, 2020). Overlaps between up- and downregulated genes in SCZ versus the other disorders were determined and tested for significance using the R function fisher.test (Harrell, 2020).

3 | RESULTS

3.1 | Literature search microglial density and morphology studies

After title and abstract screening for inclusion and exclusion criteria, 38 studies were selected for full-text assessment. Twenty-two studies were excluded (Table S4), including two studies (Busse et al., 2012; Steiner et al., 2006) containing samples that overlapped with other studies (Gos et al., 2014; Steiner et al., 2008). The study with the largest sample size was included. The database searches in PubMed and EMBASE, and additional records identified via cross-referencing, yielded a total of 16 records (Figure S1) that were all included in the qualitative assessment (Table S5). Authors of six studies (Comte, Kotagiri, & Szele, 2012; Connor, Guo, & Akbarian, 2009; Fillman et al., 2013; Foster et al., 2006; Schnieder et al., 2014; Seredenina et al., 2017) were contacted for additional information, with additional data received from two studies (Fillman et al., 2013; Schnieder et al., 2014). A total of 12 studies were included in the microglia density meta-analysis, with a total of 238 patients and 252 controls (Table S6). These studies encompassed 12 different brain regions. Most studies analyzed microglial density and a few studies also investigated changes in microglial morphology. Various markers were used to visualize microglia: HLA-DR, Iba1, CD68, and NOX2. NOX2 was used in only one study (Seredenina et al., 2017) (Table S7). HLA-DR and CD68 are upregulated on activated microglia, whereas Iba1 is more stably expressed. NOX2 has not been used before for assessing microglial density, but the authors show that the protein is expressed on microglia, and this was confirmed by the study of Patir (Patir et al., 2019). An overview of the included studies and extracted data can be found in Tables S5-8.

3.2 | Quality assessment

A quality assessment was performed for all studies assessing methodology, study design, and reporting. The overall quality of the studies was rated high. Most studies ruled out neuropathology, described their applied methods extensively, performed case–control matching, and reported important confounders (age/PMI/sex). Correction for these confounders was also often applied. As expected, more recent studies scored higher on these quality measures than some of the initial studies. As microglia activation can be caused by a variety of reasons, a full description of demographics can be helpful. However, this was present in only half of the studies.

3.3 | Review and meta-analysis of microglial density

A random-effects meta-analysis was performed on 12 studies to analyze differences in microglial density irrespective of brain region. Estimated ES for different brain regions within one study was nested to prevent overrepresentation. Figure 1a showed no significant differences in microglial density between SCZ patients and controls (ES: 0.154 95% CI: 0.113-0.212, p = .258). Unnestes data displayed similar results (ES: 0.183 95% CI: 0.000 to 0.365 p = .05; Figure S2). The heterogeneity for the studies was low to moderate (I^2 = 18.9%), and the variability between studies was not significant (Q = 18.4, p = .06). Inspection of the funnel plot and the Egger's test showed indication for publication bias (p = .01) (Figure S4). Two studies were defined as potential outlier studies, exceeding residual z-scores of 1.96 (Radewicz, Garey, Gentleman, & Reynolds, 2000; Wierzba-Bobrowicz, Lewandowska, Lechowicz, Stepień, & Pasniewski, 2005)). Sensitivity analysis, excluding these outlier studies, indicated no significant differences between SCZ and controls in microglia cell density (ES: 0.010 95% CI: 0.97 to 0.217). A meta-regression analysis checked for potential confounder variables (age, gender, pH, and PMI) showed...
that none of these variables had a significant effect on the outcome ($p > .05$; data not shown). An exploratory subgroup analysis was performed to assess possible sources of variation. No significant differences were observed in microglia density between different microglia markers (HLA-DR, CD68, IBA1, NOX2), automated or manual counting methods, or cortical or subcortical studies (data not shown). When segregating the analysis per brain regions, we found a significant increase in microglial density in the temporal cortex (ES: 2.27 95% CI: 1.46–3.09, $p < .001$, Q-between = 29.72; $p < .001$) in SCZ patients, but this was not observed in the other brain regions (frontal and occipital cortex or limbic system; Figure S3). However, the two temporal cortex studies were identified as potential outliers, exceeding residual $z$-scores of 1.96 (Radewicz et al., 2000; Wierzba-Bobrowicz et al., 2005).

### Review of microglial morphology

Table S8 provides an overview of studies that assessed the morphology of microglia in SCZ. Three studies did not observe morphological changes (Brisch et al., 2017; Petrasch-Parwez et al., 2020; Schneider et al., 2014). Three studies reported morphological differences between patients and controls, but the direction of results was different: Wierzba et al. reported an increased density of both ramified and amoeboid cells (Wierzba-Bobrowicz et al., 2005); Hercher et al. reported the presence of cells with an amoeboid morphology in white matter in 3/20 SCZ patients but none of the controls (Hercher, Chopra, & Beasley, 2014); while Radewicz et al. reported that microglia tended to have more ramified processes in SCZ (Radewicz et al., 2000).
### 3.5 Microglial density and morphology NBB and EBB

To further explore previous findings in the temporal cortex, microglial density and morphology were assessed in a new postmortem brain tissue SCZ cohort using immunostainings for microglial marker Iba1 (Figure 1b,c). Morphological assessment did not show microglia differences between patients and controls (Table S9). We quantified microglial density using two parameters: Iba1-covered area and Iba1− cells/mm². The correlation between these parameters was 0.57 (p = .008). The number of Iba1− cells/mm² and total Iba1-covered area were not different from controls (Iba1−cells/mm²: SCZ: 111.3 ± 34.1; control 107.4 ± 55.0, p = .82; Iba1-covered area: SCZ: 5.28 ± 2.35; control 5.23 ± 1.69, p = .47). Age, PMI and pH were associated with microglial density and Iba1-covered area. Controlling for these covariates using an ANCOVA did not change this result (Iba1−-cells/mm²: F₁,₁₄ = 0.10, p-value = .74, partial η² = 0.008; total Iba1-covered area: F₁,₁₄ = 0.35, p-value = .57, partial η² = 0.03). The current study was included in the meta-analysis described before (Figures S10–S12). Overall, the results did not change and microglial density did not differ between SCZ patients and controls (ES: 0.144 95% CI: 0.102–0.390, p = .250; Figure S10). When analyzing the different brain regions including the current study, we still found a significant increase in microglial density in the temporal cortex compared to the other brain regions, albeit the effect size was smaller (ES: 1.256 95% CI: 0.55–1.96, p < .001, Q_between = 16.4, p < .001; Figure S12).

### 3.6 Microglial gene expression studies

Following our systematic search for gene expression of microglial markers, 85 records were found in PubMed and EMBASE, from which seven studies were finally included (Figure S5; Table S10). An overview of quality assessment, included studies in meta-analysis, and extracted data can be found in Tables S11–S13. A total of 255 patients and 261 controls were analyzed (Table S12). These studies encompassed four different brain regions (frontal including DLPFC), temporal, cingulate cortex, and hippocampus (Table S13).

### 3.7 Review and meta-analysis of expression microglial markers

A random-effect meta-analysis revealed a significant decrease in gene expression of microglial markers for unnested outcomes (ES: −0.420 95% CI −0.216 to −0.624, p < .0001, Figure 2). Exploratory subgroup analyses revealed a significant decreased expression of microglial genes in cortical tissues (ES: −0.553 95% CI −0.817 to −0.290, p < .0001), but

---

**Microglial gene expression**

| Marker | Brain region | Study | Hedges’s g | Lower limit | Upper limit | p-Value |
|--------|--------------|-------|------------|-------------|-------------|---------|
| ALF1   | DLPFC        | Lopez-Gonzalez et al. (2019) | -0.479 | -1.209 | 0.251 | 0.198 |
| ALF1   | Cingulate cortex | Seredenina et al. (2017) | -0.526 | -1.015 | -0.037 | 0.035 |
| ALF1   | Frontal cortex | Fiorentino et al. (2016) | -1.324 | -2.193 | -0.456 | 0.003 |
| CD68   | DLPFC        | Lopez-Gonzalez et al. (2019) | -0.845 | -1.598 | -0.093 | 0.028 |
| CSF1R  | DLPFC        | Lopez-Gonzalez et al. (2019) | -0.102 | -0.590 | 0.368 | 0.683 |
| HLA-DRA Temporal cortex | Durrenberger et al. (2015) | -0.723 | -1.659 | 0.213 | 0.130 |
| HLA-DRA DLPFC | Nakatani et al. (2006) | -0.555 | -1.623 | 0.513 | 0.308 |
| HLA-DRA Hippocampus | Sinkus et al. (2013) | 0.054 | -0.467 | 0.568 | 0.797 |
| HLA-DRB4 Temporal cortex | Durrenberger et al. (2015) | -1.403 | -2.522 | -0.284 | 0.014 |
| HLA-DRB4 Temporal cortex | Schmitt et al. (2011) | -0.188 | -1.235 | 0.860 | 0.726 |
| ITGAM Cingulate cortex | Seredenina et al. (2017) | -0.256 | -0.735 | 0.223 | 0.295 |
| NOX2 Frontal/ cingulate cortex | Seredenina et al. (2017) | -0.074 | -0.562 | 0.415 | 0.767 |
| TGFβ1  | DLPFC        | Lopez-Gonzalez et al. (2019) | -0.300 | -1.023 | 0.424 | 0.417 |

**OVERALL**

![Figure 2](https://wileyonlinelibrary.com)  
**Meta-analysis on expression of microglial genes.** Forest plot of primary meta-analysis on expression of microglial genes. Studies are ordered by the microglial gene that was studied. The column “Brain region” refers to the brain region studied (DLPFC-Dorsolateral Prefrontal Cortex; ACC-Anterior Cingulate Cortex; mACC-mid-Anterior Cingulate Cortex). Data from different regions in one study were nested to prevent overrepresentation. The forest plots in both graphs show the data included in a random effects meta-analysis, representing effect sizes (Hedges’s g) with 95 confidence interval (CI) for differences between patients with SCZ and controls in each study. The Square size is proportional to study weight. Diamonds at the bottom of the graphs reflect the pooled effect sizes [Color figure can be viewed at wileyonlinelibrary.com]
no change in subcortical tissues (ES: −0.212 95% CI: −0.454 to 0.029, p = .08; \( Q_{\text{between}} = 3.49; p = .06 \), Figure S6). Further zooming in on brain regions, a significant decrease in temporal (ES: −0.744 95% CI: −1.361 to −0.128, p = .018) and frontal cortex (ES: −0.541 95% CI: 0.810 to −0.218, p = .001) was observed, but no change in regions related to the limbic system (ES: −0.213 95% CI: −0.461 to 0.035, p = .092; \( Q_{\text{between}} = 3.87; p = .14 \), Figure S7). We found a significant decrease for the marker AIF1 (ES: −0.694 95% CI: −1.168 to −0.220, p < .004), but not for HLA-DR (\( Q_{\text{between}} = 4.53; p = .60 \), Figure S8). The heterogeneity was low to moderate (\( I^2 = 26.7% \)). The Q-value indicated no significant variability between studies (Q = 19.1, p = .162). The funnel plot and Egger’s test indicated the presence of publication bias (p = .001; Figure S9). One study was defined as a potential outlier (Durrenberger et al., 2015). Sensitivity analysis, excluding this potential outlier study, did not change the results (ES: −0.319 95% CI: −0.490 to −0.148, p < .0001). None of the potential moderators (gender, age, PH, PMI and brain bank) were associated with the ES or significantly changed heterogeneity (data not shown).

### 3.8 Microglial gene expression NBB and EBB

mRNA expression was determined for a panel of 16 microglia-specific markers in the temporal cortex of SCZ patients and controls (Table 1). CSF1R, IFR8, ITGAX, OLR1, and TMEM119 were significantly downregulated. CX3CR1, HLA-DRA, ITGAM, ITGB2, and P2RY12 were also downregulated in SCZ patients (Figure 3a), but these genes did not survive correction for multiple testing. Age, sex, and PMI were associated with microglial gene expression. However, controlling for age, sex, and PMI using an ANCOVA did not change the results, except ITGAM lost significance after correction (\( F_{1,18} = 5.3; p = .06 \), Figure S8). No significant differences were observed for AIF1, CD68, GPR34, ITGAM, ITGB2, TREM2, TYROBP between SCZ patients and controls. We included our novel data of the NBB/EBB cohort in our meta-analysis of published studies (Figure S13–S16). These analyses also showed a significant decrease in gene expression of core microglial genes (ES: −0.417 95% CI: −0.417 to −0.546, p < .0001; Figure S13). To further validate these findings, we compared our qPCR results with results of the most recent transcriptome meta-analysis (Gandal, Zhang, et al., 2018) (Table 1). CSF1R, OLR1, IFR8, CX3CR1, HLA-DR, ITGAM, ITGAX, P2RY12, and TMEM119 were significantly downregulated in both studies. Altogether, we found an unaltered density of Iba1+ cells, but decreased gene expression of several microglial markers. These results could be an indication of an altered overall microglial phenotype with decreased expression of several markers. However, recent studies have shown that microglia are a heterogeneous cell population that consists of clusters with different...
characteristics (Grabert et al., 2016; Masuda, Sankowski, Staszewski, & Prinz, 2020; Mathys et al., 2017; Prinz, Priller, Sisodia, & Ransohoff, 2011; Van Wageningen et al., 2019). The separation between some of these clusters and macrophages is challenging. Our results could, therefore, also reflect shifts in subclusters of microglia/myeloid cells. To further explore these two possibilities at the protein level, we performed double-labeled immunostainings with Iba1 and TMEM119 antibodies (Figure 3b). Co-localization analysis showed that SCZ patients had significantly less microglia that were positive for both Iba1 and TMEM119 in the temporal cortex ($p = .027$) (Figure 3c), which indicates a shift in subsets of microglia/myeloid cells. We observed donor-donor differences in the morphology of TMEM119$^+$ cells, but did not find an association with disease status.

3.9 Comparing the expression levels of microglia-specific genes in bulk tissue across disorders

To further understand how the phenotype of microglia is changed in SCZ, a set of microglia-specific genes ($N = 243$) (Patir et al., 2019) and available results from the aforementioned transcriptome study (Gandal, Zhang, et al., 2018) were analyzed. In SCZ, 90/243 microglia-specific genes are downregulated, and 7 are upregulated (Table S14). Downregulated genes include $C3$, $P2RY12$, $P2RY13$, $CSF1R$, $CX3CR1$, $TMEM119$, $ITGAM$, $ITGAX$, $OLFML3$. A cross-disorder analysis demonstrated that expression changes of these microglia-specific genes are correlated between SCZ and ASD or BD (Figure 4a). Interestingly, most of these 243 microglia-specific genes were upregulated in AD, but downregulated in SCZ (Figure 4b). Thirty-seven genes showed an
opposite effect in these disorders, being upregulated in AD and downregulated in SCZ. These included CD33, TREM2, TMEM119, CSF1R, and TLR10.

4 | DISCUSSION

The aim of the present study was to provide an update of the microglial changes that have been found in postmortem brain tissue of patients with SCZ. We systematically investigated published studies assessing microglial cell density, morphology and expression of microglial genes in postmortem brain tissue of SCZ patients and performed additional experiments on temporal cortex of a separate and new cohort.

FIGURE 4 Cross-disorder analysis. (a) Comparison between transcriptional changes of a set of microglial signature genes (N = 243) in bulk brain tissue across diseases. Log2 fold changes of 243 core microglial genes assessed in cortex of patients with schizophrenia (SCZ) (Gandal, Zhang, et al., 2018), plotted against the log2 fold changes reported in cortex of patients with Alzheimer's Disease (AD) (Friedman et al., 2018), Autism Spectrum Disorder (ASD) and Bipolar Disorder (BD) (Gandal, Zhang, et al., 2018). Spearman correlation and p-values are provided. (b) Overlaps between the number of microglia signature genes up- or downregulated in SCZ, ASD, AD, and BD. Well-known microglial markers are highlighted; genes in bold are significantly upregulated in AD, but downregulated in SCZ [Color figure can be viewed at wileyonlinelibrary.com]

4.1 | Microglial density and morphology in SCZ

Previous reviews by Trepanier and Van Kesteren reported evidence for an increased microglial density in SCZ (Trépanier et al., 2016; Van Kesteren et al., 2017). Here, we included 10 additional studies (Brisch et al., 2017; Durrenberger et al., 2015; Fiorentino et al., 2016; López-González et al., 2019; Nakatani et al., 2006; Petrasch-Parwez et al., 2020; Schmitt et al., 2011; Schnieder et al., 2014; Seredenina et al., 2017; Sinkus, Adams, Logel, Freedman, & Leonard, 2013) and excluded two studies with overlapping samples (Gos et al., 2014; Steiner et al., 2008), as well as one study that had a strong effect in the previous reviews (ES: 1.79 95% CI 0.76–2.83), but was retracted because of data falsification (Rao, Kim, Harry, Rapoport, & Reese, 2013). In addition, we applied a nesting approach on studies
including multiple brain regions. The heterogeneity of our updated meta-analysis was lower compared to the previous study (Van Kesteren et al., 2017), and we no longer found a significant difference in microglial density in SCZ. A significantly increased microglial density was only found in the temporal cortex. However, that result was based on two smaller studies \((N = 18\) and \(N = 17\) in total) (Radewicz et al., 2000; Wierzbowa-Bobrowicz et al., 2005) that were identified as potential outliers with methodological limitations, as reported in the qualitative assessment. In addition, we were not able to validate an increased density in the temporal cortex of an additional cohort, with the limitation that the sample size of our additional cohort was also limited \((N = 28\) in total). Although we found several studies reporting on morphological changes, the results were inconsistent, which is probably related to the large variety of read-outs that were used on studies with small sample sizes and the challenges in quantifying morphological assessments.

4.2 | Microglial gene expression in SCZ

The previous reviews reported indications for neuroinflammation. In both studies, the authors included mRNA and protein expression of a variety of inflammatory markers (Trépanier et al., 2016; Van Kesteren et al., 2017), such as IL-6, IL-1β, and IL-8, which are not specific to microglia, but are also expressed in astrocytes and other cell types in the brain. In addition, the results were heterogeneous and except for an increased expression of IL6, increased expression of these markers was not found in the most recent and robust transcriptome meta-analysis (Gandal, Zhang, et al., 2018). Since we were specifically interested in microglia, we only included expression of a set of microglial-specific genes (Patir et al., 2019). Our qPCR analysis, our meta-analysis, and the most recent genome-wide transcriptomic analysis all show a consistent decreased expression of several microglial genes, including the well-known markers HLA-DR and ITGAM. It would be interesting to understand how the observed findings relate to the binding of the TSPO tracer. Positron emission tomography studies with TSPO tracers have been often used to analyze neuroinflammation or microglial activation in vivo. TSPO PET studies in schizophrenia patients have shown heterogeneous results. While the earlier studies reported increased binding of the tracers, more recent studies did not find this effect or even a lower binding (Marques et al., 2019; Plevé-Sigray et al., 2018). Moreover, there is a debate about what type of changes in glial cells are reflected by changes in TSPO binding (Notter, Coughlin, Sawa, & Meyer, 2018; Owen et al., 2017; Sneebor et al., 2020). Our current study illustrates that microglial changes go beyond the activated/non-activated dichotomy. The microglia signature that we describe here may provide novel molecular imaging targets.

4.3 | Translation of gene expression changes to cellular changes

In our meta-analysis and additional immunostainings, we did not find indications for changes in microglial density. In our gene expression analyses, we found decreased expression of several microglia-specific genes, including P2RY12, CSF1R, and TMEM119. To further explore these findings at the cellular level, we performed a staining with Iba1 and TMEM119 and found a decreased percentage of Iba1 cells expressing TMEM119. TMEM119 has recently been identified as a marker that is highly specific to microglia (Bennett et al., 2016; Satoh et al., 2016). In contrast to Iba1, which is also expressed on infiltrating macrophages (Imai, Ibata, Ito, Ohsawa, & Kohsaka, 1996; Ohsawa, Imai, Kanazawa, Sasaki, & Kohsaka, 2000), it is exclusively expressed on microglia. Although the function of TMEM119 is still unknown, it has been identified as a downstream target of PU.1, a protein that is involved in microglia development (Satoh et al., 2016). TMEM119 is highly expressed on subclusters of microglial cells with more homeostatic properties, and this subcluster is partly lost with increasing age and in neurodegeneration as observed in Alzheimer’s disease and amyotrophic lateral sclerosis brain tissue (Chiu et al., 2013; Holtman et al., 2015; Krasemann et al., 2017; Olah et al., 2018; Orre et al., 2014). These results suggest that microglia in schizophrenia do not all show the same changes in phenotype, but that there is a change in the composition of the microglia population in schizophrenia, similar to what has been shown for neurodegenerative disorders (Srinivasan et al., 2020). In addition, it is important to note that Iba1 is a marker that is often used as a marker for microglia, but that this marker is not restricted to microglia and also expressed at lower levels on for instance, infiltrating macrophages (Imai et al., 1996; Ohsawa et al., 2000). We performed a systematic search for the macrophage markers ITGAA4, CD44, CD169, CD38, CD11a, PDL1 (see Figure S17) (Bowman et al., 2016; Greter, Lelios, & Croxford, 2015; Gu et al., 2016; Mrdjen et al., 2018), but we did not find any relevant articles. In addition, we extracted the data of these markers from the largest transcriptome meta-analysis to date (Gandal, Haney, et al., 2018; Gandal, Zhang, et al., 2018). Except for a decreased expression of CD44, we found no indications for SCZ-associated changes in infiltrating macrophages (Table S15). Analyses at the single-cell level, such as mass cytometry (Böttcher et al., 2019; Sneebor et al., 2019; Snijders et al., 2020) or single nuclei RNA-seq (Masuda et al., 2020; Mathys et al., 2019) are needed to further understand how the composition of myeloid cells is changed in schizophrenia.

4.4 | Interpretation of the identified SCZ-associated microglial gene expression changes

Here we describe a panel of various microglial-specific genes that are consistently downregulated in SCZ. These changes showed similarities with other psychiatric disorders, but a distinct profile from AD. An important limitation for this cross-disorder analysis, however, is that the AD data were derived from a separate transcriptome analysis (Friedman et al., 2018) rather than the combined analysis of different psychiatric disorders (Gandal, Zhang, et al., 2018). Many factors can potentially be involved in causing this SCZ-related microglial profile, characterized by a loss of mature characteristics but without signs of overt immune activation. We have summarized some of the potential...
candidates in Figure 5. This includes a response of microglia to stress, a well-known risk factor for developing psychiatric disorders (Zorn et al., 2017). Animal studies revealed that stress can induce a down-regulation of similar microglial markers as observed in SCZ postmortem brain tissue, such as CX3CR1, P2RY12, and TGFBR1 (Park et al., 2019). This microglial phenotype may also be a consequence of disrupted TGF-β signaling, which is important for inducing and maintaining the distinct profile of microglia (Butovsky et al., 2014; Gosselin et al., 2017). The changes we observed showed a high resemblance with changes induced by culturing microglia after isolating them from postmortem brain tissue. However, these changes are counteracted when the cells are supplemented with TGF-β (Gosselin et al., 2017). An overrepresentation of the TGF-β signaling pathway in SCZ risk genes further supports this hypothesis (Chavarría-Siles et al., 2007; Frydecka et al., 2013). Upstream from those gene expression changes might be epigenetic changes previously described for SCZ. The largest methylation study to date (Jaffe et al., 2015) found differential methylation of several transcription factors that are related to microglia development and phenotype, including MAFB, FOS, RUNX1, and MEF2C (Gosselin et al., 2017; Jaffe et al., 2015; van Mierlo et al., 2019). In addition to these potential causal pathways, this microglial signature may have also been triggered by any of the consequences of having SCZ, such as the use of medication (A. Bloomfield et al., 2018; Cotel et al., 2015; Kato et al., 2011) or an altered lifestyle since unhealthy diet, less physical activity and sleep, and obesity can all cause changes in microglia (Ingiosi, Opp, & Krueger, 2013; Jamatia et al., 2018; Valero, Paris, & Sierra, 2016).

Whether the changes that we observed are involved in causing the disease is not known yet. In Figure 6 we speculate how the observed microglial changes could potentially contribute to the pathogenesis of SCZ. This includes dysregulation of the normal functions of microglia in neuroplasticity and neurotransmission by affecting the crosstalk between microglia, neurons, and astrocytes (Cserép et al., 2020). For instance, mice with CX3CR1 deletion exhibit reduced dendritic spine pruning, abnormal synapse maturation, decreased functional connectivity, and behavioral abnormalities (Paolicelli et al., 2011). Recently, increased phagocytosis and increased inflammation were observed in a cellular model that deleted the CX3CR1 gene in microglia derived from human induced pluripotent stem cells (hiPSC), suggesting that CX3CR1 in human microglia may contribute to microglial homeostasis by regulating inflammatory response and phagocytosis (Murai et al., 2020). Abnormalities in synaptic maturation, synapse elimination and spine density are thought to underlie SCZ, but also contribute to other psychiatric disorders, including ASD and BD (Gandal, Zhang, et al., 2018; Penzes, Cahill, Jones, Vanleeuwen, & Woolfrey, 2011). In addition, these microglial changes could also be involved in dopamine dysregulation in SCZ (Jaaro-Peled, Ayhan, Pletnikov, & Sawa, 2010). P2RY12 and related genes have been shown to play an important role in dopamine signaling (Krügel, Kittner, Franke, & Illes, 2001; Trendelenburg & Bültmann, 2000; Zhang, Yamashita, Ohshita, Sawamoto, & Nakamura, 1995). Our findings stress the need for more research to understand how changes in the molecular phenotype of microglia are related to changes in microglia–
neuron interactions and how this influences brain development and function.

4.5 | Strengths and limitations

Evidence for inflammation in postmortem brain tissue of SCZ patients has been reviewed before (Trépanier et al., 2016; Van Kesteren et al., 2017), but these studies combined different types of outcomes into one analysis. This can be problematic, since gene expression, protein expression and cell density do not necessarily correlate (Liu, Beyer, & Aebersold, 2016). In this study, we used a more conservative approach by separating density measures from gene expression outcomes. In addition, we prevented the overrepresentation of particular populations by excluding studies with overlapping samples. Subgroup analysis outcomes were performed on a limited number of studies and may have been susceptible to the influence of an outlier. Our comparative analysis may provide direction in the search for underlying mechanisms through the identification of circumstances similar and different to SCZ. However, the data on SCZ we used for comparison originated from bulk brain tissue sequencing, and it recently became clear that microglia-specific changes are underrepresented in bulk data (Mathys et al., 2019). Although we selected genes that are strongly enriched in microglia, expression by other cell types could have contributed to the outcome. Thus, the exact microglia-specific changes in SCZ remain to be determined. In addition, many factors, such as neuroleptics (Kowalski, Labuzek, & Herman, 2003) and use of second-generation antipsychotics (Kato et al., 2011; Bloomfield et al., 2018; Cotel et al., 2015), cause of death, suicide attempts, somatic comorbidity (Mathys et al., 2019; Mizee et al., 2017; van der Poel et al., 2019), chronicity (Bitanihirwe & Woo, 2020), positive or negative symptomatology (Volk, 2017), age and sex may confound the results. We were not able to fully adjust for all these potential confounding effects in additional analyses due to small sample sizes in our own cohort and limited reporting across studies in the meta-analysis.

4.6 | Conclusions

Altogether we have found evidence for the presence of a distinct microglia phenotype in SCZ with potential overlap with other psychiatric disorders. The microglial gene expression changes identified in bulk brain tissue of SCZ patients need to be confirmed through sequencing of pure microglia populations by either isolating them from non-frozen brain tissue (Melfief et al., 2016) or using nuclei-based techniques (Nott et al., 2019). Single-cell/nuclei techniques (Masuda et al., 2020) will also uncover whether these changes are reflecting changes in the entire microglial population or just a subpopulation. The impact of these SCZ-associated transcriptomic alterations on microglial function and, ultimately, the influence on brain development and function is important for understanding the relevance of these findings and will rely on studies in cell-culture and animal models.

ACKNOWLEDGMENTS

This study was supported by the psychiatric donor program of the Netherlands Brain Bank (NBB-Psy), which is funded by the
Bloomfield, P. S., Bonsall, D., Wells, L., Dormann, D., Howes, O., & Bitanihirwe, B. K. Y., & Woo, T. U. W. (2020). A conceptualized model linking Borenstein, M., Hedges, L. V., Higgins, J. P. T., & Rothstein, H. R. (2009).

Berdenis van Berlekom, A., Muflihah, C. H., Snijders, G. J. L. J., Benros, M. E., Pedersen, M. G., Rasmussen, H., Eaton, W. W., Fernhoff, N. B., Missall, Cyndi, and Raphael Kubler for data sharing, the team of the Netherlands and Edinburgh Brain Bank for their services, and Ninouk Akkerman and Colin Smith for their involvement. We also thank Eduardo Garcia Reino, Roy Missall, Frederieke Gigase, and Raphael Kubler for the proofreading of the manuscript.

CONFLICT OF INTEREST
All authors reported no financial, biomedical, or potential conflict of interest to declare.

DATA AVAILABILITY STATEMENT
Data is available upon request.

ORCID
Gijisje J. L. J. Snijders https://orcid.org/0000-0002-2694-1234

REFERENCES
Bennett, M. L., Bennett, F. C., Liddelow, S. A., Ajami, B., Zamanian, J. L., Fernhoff, N. B., ... Barres, B. A. (2016). New tools for studying microglia in the mouse and human CNS. Proceedings of the National Academy of Sciences of the United States of America, 113(12), E1738–E1746. https://doi.org/10.1073/pnas.1525528113

Benros, M. E., Pedersen, M. G., Rasmussen, H., Eaton, W. W., Nordenfelt, M., & Mortensen, P. B. (2014). A nationwide study on the risk of autoimmune diseases in individuals with a personal or a family history of schizophrenia and related psychosis. American Journal of Psychiatry, 171 (2), 218–226. https://doi.org/10.1176/appi.ajp.2013.13010086

Berdenis van Berlekom, A., Mufliah, C. H., Snijders, G. J. L. J., MacGillivray, H. D., Middeldorp, J., Hol, E. M., ... de Witte, L. D. (2019). Synapse pathology in schizophrenia: A meta-analysis of postsynaptic elements in postmortem brain studies. Schizophrenia Bulletin, 46(2), 374–386. https://doi.org/10.1093/schbul/sbz060

Bergon, A., Belzreaux, R., Comte, M., Pelletier, F., Hervé, M., Gardiner, E. J., ... Ibrahim, E. C. (2015). CX3CR1 is disregulated in blood and brain from schizophrenia patients. Schizophrenia Research, 168, 434–443. https://doi.org/10.1016/j.schres.2015.08.010

Bitaninhwa, B. K. Y., & Woo, T. U. W. (2020). A conceptualized model linking matrix metalloproteinase-9 to schizophrenia pathogenesis. Schizophrenia Research, 218, 28–35. https://doi.org/10.1016/j.schres.2019.12.015

Bloomfield, P. S., Bonsall, D., Wells, L., Dormann, D., Howes, O., & Paola, V. D. (2018). The effects of haloperidol on microglial morphology and translocator protein levels: An in vivo study in rats using an automated cell evaluation pipeline. Journal of Psychopharmacology, 32 (11), 1264–1272. https://doi.org/10.1177/0269881118788830

Borenstein, M., Hedges, L. V., Higgins, J. P. T., & Rothstein, H. R. (2009). Introduction to meta-analysis. Psychotherapy Research Journal of the Society for Psychotherapy Research, 19(4–5), 421. https://doi.org/10.1002/psrj.2009.19.s41593-018-0290-2

Böttcher, C., Schlicker, S., Sneebøer, M. A. M., Kunkel, D., Knop, A., Paza, E., ... Priller, J. (2019). Human microglia regional heterogeneity and phenotypes determined by multiplexed single-cell mass cytometry. Nature Neuroscience, 22(1), 78–90. https://doi.org/10.1038/s41593-018-0290-2

Bowman, R. L., Klemm, F., Alkari, L., Pyonteck, S. M., Sevenich, L., Quail, D. F., ... Joyce, J. A. (2016). Macrophage ontogeny underlies differences in tumor-specific education in brain malignancies. Cell Reports, 17, 2445–2459. https://doi.org/10.1016/j.celrep.2016.10.052

Brisch, R., Steiner, J., Mawrin, C., Krzyżanowska, M., Jankowski, Z., & Gos, T. (2017). Microglia in the dorsal raphe nucleus plays a potential role in both suicide facilitation and prevention in affective disorders. European Archives of Psychiatry and Clinical Neuroscience, 267(5), 403–415. https://doi.org/10.1007/s00406-017-0774-1

Busse, S., Busse, M., Schiltz, K., Biebl, H., Gos, T., Brisch, R., ... Steiner, J. (2012). Different distribution patterns of lymphocytes and microglia in the hippocampus of patients with residual versus paranoid schizophrenia: Further evidence for disease course-related immune alterations? Brain, Behavior, and Immunity, 26, 1273–1279. https://doi.org/10.1016/j.bbi.2012.08.005

Butovsky, O., Jedrychowski, M. P., Moore, C. S., Clicic, R., Lanser, A. J., Gabriely, G., ... Weiner, H. L. (2014). Identification of a unique TGF-β-dependent molecular and functional signature in microglia. Nature Neuroscience, 17(1), 131–143. https://doi.org/10.1038/nn.3599

Chavarria-Siles, I., Waiss-Bass, C., Quezada, P., Dassor, A., Contreras, S., Medina, R., ... Escamilla, M. A. (2007). TGF-β-induced factor (TGFIF): A candidate gene for psychosis on chromosome 18p. Molecular Psychiatry, 12(11), 1033–1041. https://doi.org/10.1038/sj.mp.4001997

Chiu, I. M., Morimoto, E. T. A., Goodarzi, H., Liao, J. T., O’Keeffe, S., Phatnani, H. P., ... Maniatis, T. (2013). A neurodegeneration-specific gene-expression signature of acutely isolated microglia from an amyotrophic lateral sclerosis mouse model. Cell Reports, 4(2), 385–401. https://doi.org/10.1016/j.celrep.2013.06.018

Comte, I., Kotagiri, P., & Szele, F. G. (2012). Regional differences in human ependymal and subventricular zone cytoarchitecture are unchanged in neuropsychiatric disease. Developmental Neuroscience, 34, 299–309. https://doi.org/10.1159/000338600

Connor, C. M., Guo, Y., & Akbarian, S. (2009). Cingulate white matter neurons in schizophrenia and bipolar disorder. Biological Psychiatry, 66, 486–493. https://doi.org/10.1016/j.biopsych.2009.04.032

Cotiel, M. C., Lenartowicz, E. M., Natesan, S., Modo, M. M., Cooper, J. D., Williams, S. C. R., ... Vernon, A. C. (2015). Microglial activation in the rat brain following chronic antipsychotic treatment at clinically relevant doses. European Neuropsychopharmacology, 25(11), 2098–2107. https://doi.org/10.1016/j.euroneuro.2015.08.004

Cserép, C., Pósfai, B., Lénárt, N., Fekete, R., László, Z. I., Lele, Z., ... Dénès, Á. (2020). Microglia monitor and protect neuronal function through specialized somatic purinergic junctions. Science, 367, 528–537. https://doi.org/10.1126/science.aax6752

Durrenberger, P. F., Fernando, F. S., Kashefi, S. N., Bonnert, T. P., Seilhean, D., Nait-Oumesmar, B., Reynolds, R. (2015). Common mechanisms in neurodegeneration and neuroinflammation: A BrainNet Europe gene expression microarray study. Journal of Neural Transmission, 122, 1055–1068. https://doi.org/10.1007/s00702-014-1293-0

Egger, M., Smith, G. D., Schneider, M., & Minder, C. (1997). Bias in meta-analysis detected by a simple, graphical test. BMJ: British Medical Journal, 315, 629–634. https://doi.org/10.1136/bmj.315.7109.629

Fillman, S. G., Cloonan, N., Catts, V. S., Miller, L. C., Wong, J., McCrossin, T., ... Weickert, C. S. (2013). Increased inflammatory markers identified in the dorsolateral prefrontal cortex of individuals with schizophrenia. Molecular Psychiatry, 18(2), 206–214. https://doi.org/10.1038/mp.2012.110

Fiorentino, M., Sapone, A., Senger, S., Camhi, S. S., Kadielski, S. M., Buie, T. M., ... Fasano, A. (2016). Blood-brain barrier and intestinal epithelial barrier alterations in autism spectrum disorders. Molecular Autism, 7, 49. https://doi.org/10.1186/s13229-016-0110-z

Foster, R., Kendanaaratchi, A., Beasley, C., Williams, B., Khan, N., Fagerhol, M. K., & Everall, I. P. (2006). Calprotectin in microglia from frontal cortex is up-regulated in schizophrenia: Evidence for an
inflammatory process? European Journal of Neuroscience, 24, 3561–3566. https://doi.org/10.1111/j.1460-9568.2006.05219.x

Friedman, B. A., Srinivasan, K., Ayalon, G., Meilandt, W. J., Lin, H., Huntley, M. A., ... Hansen, D. V. (2018). Diverse brain myeloid expression profiles reveal distinct microglial activation states and aspects of Alzheimer's disease not evident in mouse models. Cell Reports, 22, 832–847. https://doi.org/10.1016/j.celrep.2017.12.066

Frydecka, D., Misiak, B., Beszlek, J. A., Karabon, L., Pawlak-Adamska, E., Tomkiewicz, A., ... Kieja, A. (2013). Genetic variants in transforming growth factor-β gene (TGFβ1) affect susceptibility to schizophrenia. Molecular Biology Reports, 40, 5607–5614. https://doi.org/10.1007/s11033-012-2662-8

Gandal, M. J., Haney, J. R., Parikshak, N. N., Leppa, V., Ramaswami, G., Gosselin, D., Skola, D., Coufal, N. G., Holtman, I. R., Schlachetzki, J. C. M., Greter, M., Lelios, I., & Croxford, A. L. (2015). Microglia versus myeloid cell modulations: Are antipsychotics a ‘Fire Extinguisher’ in the brain of schizophrenia? Mini-Reviews in Medicinal Chemistry, 15, 565–574. https://doi.org/10.2174/138955711795096941

Kettenmann, H., Hanisch, U.-K., Noda, M., & Verkhratsky, A. (2011). Physiology of microglia. Physiological Reviews, 91(2), 461–553. https://doi.org/10.1152/physrev.00011.2010

Kowalski, J., Labuzek, K., & Herman, Z. S. (2003). Fluoxetine and trifluoperidol reduce secretion of tumor necrosis factor-α and nitric oxide by rat microglial cells. Neurochemistry International, 43, 173–178. https://doi.org/10.1016/S0197-0186(02)00163-8

Krügel, U., Kütter, N., Franke, H., & Illes, P. (2001). Stimulation of P2 receptors in the ventral tegmental area enhances dopaminergic mechanisms in vivo. Neuropharmacology, 40, 1084–1093. https://doi.org/10.1016/S0028-3908(01)00035-8

Liberati, A., Altman, D. G., Tetzlaff, J., Mulrow, C., Gøtzsche, P. C., et al. (2009). The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: Explanation and elaboration. BMJ (Clinical Research Ed.), 339, b2700. https://doi.org/10.1136/bmj.b2700

Liu, Y., Beyer, A., & Aebensold, R. (2016). On the dependency of cellular protein levels on mRNA abundance. Cell, 165(3), 535–550. https://doi.org/10.1016/j.cell.2016.03.014

López-González, I., Pinacho, R., Vila, È., Escanilla, A., Ferrer, I., & Ramos, B. (2017). Temporal tracking of microglia activation in neurodegeneration at single-cell resolution. Cell Reports, 23, 2186–2196. https://doi.org/10.1016/S2211-1247(17)31305-7

Masuda, T., Sankowski, R., Staszewski, O., & Prinz, M. (2020). Microglia heterogeneity in the single-cell era. Cell Reports, 30, 1271–1281. https://doi.org/10.1016/j.celrep.2020.01.010

Mathys, H., Adalikkan, C., Gao, F., Young, J. Z., Manet, E., Hemberg, M., ... Tsai, L. H. (2017). Temporal tracking of microglia activation in neurodegeneration at single-cell resolution. Cell Reports, 21, 366–380. https://doi.org/10.1016/j.celrep.2017.09.039

Mathys, H., Davila-Velderrain, J., Peng, Z., Gao, F., Mohammadi, S., Young, J. Z., ... Tsai, L.-H. (2019). Single-cell transcriptomic analysis of...
Alzheimer’s disease. Nature, 570(7761), 332–337. https://doi.org/10.1038/s41586-019-1195-2
Melief, J., Sneeboer, M. A. M., Litjens, M., Ormel, P. R., Palmen, S. J. M. C., Huitinga, I., ... de Witte, L. D. (2016). Characterizing primary human microglia: A comparative study with myeloid subsets and culture models. Glia, 64(11), 1857–1868. https://doi.org/10.1002/glia.23023
Millar, T., Walker, R., Arango, J. C., Ironside, J. W., Harrison, D. J., MacIntyre, D. J., ... Bell, J. E. (2007). Tissue and organ donation for research in forensic pathology: The MRC sudden death brain and tissue bank. Journal of Pathology, 213, 369–375. https://doi.org/10.1002/path.2247
Mizee, M. R., Miedema, S. S. M., van der Poel, M., Schuurman, K. G., van Murai, N., Mitalipova, M., & Jaenisch, R. (2020). Functional analysis of Iba1-immunopositive microglial cells in the anterior midcingulate cortex of schizophrenia and bipolar disorder. European Archives of Psychiatry and Clinical Neuroscience, 270, 819–828. https://doi.org/10.1007/s00406-020-01107-0
Plavén-Sigray, P., Matheson, G. J., Collste, K., Ashok, A. H., Coughlin, J. M., Howes, O. D., ... Cervenka, S. (2018). Positron emission tomography studies of the glial cell marker translocator protein in patients with psychosis: A meta-analysis using individual participant data. Biological Psychiatry, 84(6), 433–442. https://doi.org/10.1007/j.biopsych.2018.02.1171
Pouget, J. G., Han, B., Wu, Y., Mignot, E., Ollila, H. M., Barker, J., ... Knight, J. (2019). Cross-disorder analysis of schizophrenia and 19 immune-mediated diseases identifies shared genetic risk. Human Molecular Genetics, 28, 3498–3513. https://doi.org/10.1093/hmg/ddz145
Powchik, P., Davidson, M., Haroutunian, V., Gabriel, S. M., Purohit, D. P., Perl, D. P., ... Davis, K. L. (1998). Postmortem studies in schizophrenia. Schizophrenia Bulletin, 24, 325–341. https://doi.org/10.1093/oxfordjournals.schbul.a003330
Prinz, M., Priller, J., Sisodia, S. S., & Ransohoff, R. M. (2011). Heterogeneity of CNS myeloid cells and their roles in neurodegeneration. Nature Neuroscience, 14, 1227–1235. https://doi.org/10.1038/nn.2923
Rademaker, M. C., de Lange, G. M., & Palmen, S. J. M. C. (2018). The Netherlands brain Bank for Psychiatry. Handbook of Clinical Neurology, 150, 3–16. https://doi.org/10.1016/B978-0-444-63639-3.00001-3
Radewicz, K., Carey, L. J., Gentleman, S. M., & Reynolds, R. (2000). Increase in HLA-DR immunoreactive microglia in frontal and temporal cortex of chronic schizophrenics. Journal of Neuropathology and Experimental Neurology, 59(2), 137–150.
Rao, J. S., Kim, H. W., Harry, G. J., Rapoport, S. I., & Reese, E. A. (2013). Increased neuroinflammatory and arachidonic acid cascade markers, and reduced synaptic proteins, in the postmortem frontal cortex from schizophrenia patients. Schizophrenia Research, 147, 24–31. https://doi.org/10.1016/j.schres.2013.02.017
Ripke, S., Neale, B. M., Corvin, A., Walters, J. T. R., Farh, K.-H., Holmans, P. A., ... O’Donovan, M. C. (2014). Biological insights from 108 schizophrenia-associated genetic loci. Nature, 511(7510), 421–427. https://doi.org/10.1038/nature13595
Saitoh, J., Kino, Y., Azahina, N., Takamaki, M., Miyoshi, J., Ishida, T., & Saito, Y. (2016). TMEM119 marks a subset of microglia in the human brain. Neuron, 91(1), 39–49. https://doi.org/10.1011/neup.12235
Smidt, A., Leonard-Essmann, F., Durrenberger, P. F., Parlapani, E., Schneider-Axmann, T., Spanagel, R., ... Gebicke-Haerter, P. J. (2011). Regulation of immune-modulatory genes in left superior temporal cortex of schizophrenia patients: A genome-wide microarray study. World Journal of Biological Psychiatry, 12, 201–215. https://doi.org/10.3109/15622975.2010.530690
Snedeker, T. P., Trencevskia, I., Rosoklija, G., Stankov, A., Mann, J. J., Smiley, J., & Dwork, A. J. (2014). Microglia of prefrontal white matter in suicide. Journal of Neuropathology and Experimental Neurology, 73(9), 880–890. https://doi.org/10.1097/NEN.0000000000000107
Sekar, A., Bias, A. R., de Rivera, H., Davis, A., Hammond, T. R., Kamitaki, N., ... McC Carroll, S. A. (2016). Schizophrenia risk from complex variation of complement component 4. Nature, 530(7589), 177–183. https://doi.org/10.1038/nature16549
Sellgren, C. M., Gracias, J., Wuttuff, B., Blag, J. D., Thanos, J. M., Whittridge, P. B., ... Perls, R. H. (2019). Increased synapse elimination by microglia in schizophrenia patient-derived models of synaptic...
pruning. Nature Neuroscience, 22(3), 374–385. https://doi.org/10.1038/s41593-018-0334-7

Seredenina, T., Sorce, S., Herrmann, F. R., Ma Mulone, X.-J., Plastre, O., Aguzzi, A., ... Krause, K.-H. (2017). Decreased NOX2 expression in the brain of patients with bipolar disorder: Association with valproic acid prescription and substance abuse. Translational Psychiatry, 7(8), e1206. https://doi.org/10.1038(tp.2017.175

Sirkus, M. L., Adams, C. E., Logel, J., Freedman, R., & Leonard, S. (2013). Expression of immune genes on chromosome 6p21.2-22.1 in schizophrenia. Brain, Behavior, and Immunity, 32, 51–62. https://doi.org/10.1016/j.bbi.2013.01.087

Snoeber, M. A. M., Snoebers, G. J. L. J., Berdowski, W. M., Fernández-Andreu, A., van Mierlo, H. C., Berdenis van Berlekomp, A., ... de Witte, L. D. (2019). Microglia in post-mortem brain tissue of patients with bipolar disorder are not immune activated. Translational Psychiatry, 9(1), 153. https://doi.org/10.1038/s41398-019-0490-x

Snoeber, M. A. M., van der Doef, T., Litjens, M., Psy, N. B. B., Melief, J., Hol, E. M., ... de Witte, L. D. (2020). Microglial activation in schizophrenia: Is translocator 18 kDa protein (TSPO) the right marker? Schizophrenia Research, 215, 167–172. https://doi.org/10.1016/j.schres.2019.10.045

Snijders, G. J. L. J., Snoeber, M. A. M., Fernández-Andreu, A., Udine, E., Boks, M. P., Ormel, P. R., ... de Witte, L. D. (2020). Distinct non-innominates of microglia in post-mortem brain tissue of patients with major depressive disorder. Molecular Psychiatry, 1–14. https://doi.org/10.1038/s41380-020-00896-z

Sriniwasan, K., Friedman, B. A., Etxeberria, A., Huntley, M. A., van der Brug, M. P., Foreman, O., ... Hansen, D. V. (2020). Alzheimer’s patient microglia exhibit enhanced aging and unique transcriptional activation. Cell Reports, 31, 107694. https://doi.org/10.1016/j.celrep.2020.10.090

Steiner, J., Bielau, H., Brisch, R., Danos, P., Ullrich, O., Mawrin, C., ... Bogerts, B. (2008). Immunological aspects in the neurobiology of suicide: Elevated microglial density in schizophrenia and depression is associated with suicide. Journal of Psychiatric Research, 42(2), 151–157. https://doi.org/10.1016/j.jpsychires.2006.10.013

Steiner, J., Mawrin, C., Ziegeler, A., Bielau, H., Ullrich, O., Bernstein, H. G., & Bogerts, B. (2006). Distribution of HLA-DR-positive microglia in schizophrenia reflects impaired cerebral lateralization. Acta Neuropathologica, 112, 305–316. https://doi.org/10.1007/s00401-006-0090-9

Stephan, A. H., Barres, B. A., & Stevens, B. (2012). The complement system: An unexpected role in synaptic pruning during development and disease. Annual Review of Neuroscience, 35, 369–389. https://doi.org/10.1146/annurev-neuro-061010-113910

Suzuki, H., Ohgidani, M., Kuwano, N., Chrétien, F., Lorin de la Grandmaison, G., Onaya, M., ... Kato, T. A. (2019). Suicide and microglia: Recent findings and future perspectives based on human studies. Frontiers in Cellular Neuroscience, 13, 31. https://doi.org/10.3389/fncel.2019.00031

Tambuyzer, B. R., Ponsaerts, P., & Nouwen, E. J. (2009). Microglia: Gatekeepers of central nervous system immunity. Journal of Leukocyte Biology, 85, 352–370. https://doi.org/10.1189/jlb.0608385

Torres-Platas, S. G., Cauceanu, C., Chen, G. G., Turecki, G., & Mechawar, N. (2014). Evidence for increased microglial priming and macrophage recruitment in the dorsal anterior cingulate white matter of depressed suicides. Brain, Behavior, and Immunity, 42, 50–59. https://doi.org/10.1016/j.bbi.2014.05.007

Trendelenburg, A. U., & Bültmann, R. (2000). P2 receptor-mediated inhibition of dopamine release in rat neostriatum. Neuroscience, 96, 249–252. https://doi.org/10.1016/S0306-4522(99)00577-1

Téranier, M. O., Hopperton, K. E., Mizrahi, R., Mechawar, N., & Bazinet, R. P. (2016). Postmortem evidence of cerebral inflammation in schizophrenia: A systematic review. Molecular Psychiatry, 21(8), 1009–1026. https://doi.org/10.1038/mp.2016.90

Uptegrove, R., Manzanares-Teson, N., & Barnes, N. M. (2014). Cytokine function in medication-naive first episode psychosis: A systematic review and meta-analysis. Schizophrenia Research, 155, 101–108. https://doi.org/10.1016/j.schres.2014.03.005

Valero, J., Paris, I., & Sierra, A. (2016). Lifestyle shapes the dialogue between environment, microglia, and adult neurogenesis. ACS Chemical Neuroscience, 7, 442–453. https://doi.org/10.1021/acschemneuro.6b00009

van der Poel, M., Ulas, T., Mizee, M. R., Hsiao, C. C., Miedema, S. S., Schuurman K. G., ... Huitinga, I. (2019). Transcriptional profiling of human microglia reveals grey–white matter heterogeneity and multiple sclerosis-associated changes. Nature Communications, 10, 1139. https://doi.org/10.1038/s41467-019-08976-7

Van Kesteren, C. F. M. G., Remmers, H., van Leeuwen, L. D., Hol, E. M., van Gool, A. R., Falkai, P. G., ... Sommer, I. E. C. (2017). Immune involvement in the pathogenesis of schizophrenia: A meta-analysis on post-mortem brain studies. Translational Psychiatry, 7(3), e1075. https://doi.org/10.1038/tpp.2017.4

van Mierlo, H. C., Schot, A., Boks, M. P. M., & de Witte, L. D. (2019). The association between schizophrenia and the immune system: Review of the evidence from unbiased ‘omic-studies’. Schizophrenia Research, 217, 114–123. https://doi.org/10.1016/j.schres.2019.05.028

Van Wageningen, T. A., Vlaar, E., Kool, G., Jongenelen, C. A. M., Geurts, J. J. G., & Van Dam, A. M. (2019). Regulation of microglial temporally coincide immunoreactivity in multiple sclerosis white and grey matter lesions is dependent on their inflammatory environment. Acta Neuropathologica Communications, 7, 206. https://doi.org/10.1186/s40478-019-0850-2

Vandesompele, J., De Preter, K., Pattyn, F., Poppe, B., Van Roy, N., De Paepe, A., & Speleman, F. (2002). Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biology, 3(7), research0034.1

Volk, D. W. (2017). Role of microglia disturbances and immune-related marker abnormalities in cortical circuitry dysfunction in schizophrenia. Neurobiology of Disease, 99, 58–65. https://doi.org/10.1016/j.nbd.2016.12.019

Wang, A. K., & Miller, B. J. (2018). Meta-analysis of cerebrospinal fluid cytokine and tryptophan catabolite alterations in psychiatric patients: Comparisons between schizophrenia, bipolar disorder, and depression. Schizophrenia Bulletin, 44(1), 75–83. https://doi.org/10.1093/schbul/sbx035

Wieczorek-Bobrowicz, T., Lewandowska, E., Lechowicz, W., Stepie, T., & Pasznik, E. (2005). Quantitative analysis of activated microglia, ramiﬁcation and damage of processes in the frontal and temporal lobes of patients with multiple sclerosis-associated changes. Folia Neuropathologica, 43(2), 81–89.

Zhang, Y. X., Yamashita, H., Ohshita, T., Sawamoto, N., & Nakamura, S. (1995). ATP increases extracellular dopamine level through stimulation of P2Y purinoceptors in the rat striatum. Brain Research, 691, 205–212. https://doi.org/10.1016/0006-8993(95)00676-H

Zorn, J. V., Schür, R. R., Boks, M. P., Kahn, R. S., Joëls, M., & Vinkers, C. H. (2017). Cortisol stress reactivity across psychiatric disorders: A systematic review and meta-analysis. Psychoneuroendocrinology, 77, 25–36. https://doi.org/10.1016/j.psyneuen.2016.11.036

SUPPORTING INFORMATION

Additional supporting information may be found online in the Supporting Information section at the end of this article.

How to cite this article: Snijders GJLJ, van Zuiden W, Snoeber MAM, et al. A loss of mature microglial markers without immune activation in schizophrenia. Glia. 2021;1–17. https://doi.org/10.1002/glia.23962